Drug Trial Radar · NCT06719908
A Phase I Study of the Interaction of Alcohol With Oral AFA-281 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Dec 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Jul 1, 2025
Primary completion
Jul 1, 2026
Study completion Sep 1, 2029
Sponsor
- Lead sponsor
- Afasci IncIndustry
- Sponsor type
- Industry
- First posted
- Dec 6, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate if alcohol interacts with the drug candidate AFA-281 in adults (healthy volunteers). This trial will evaluate blood concentration levels of AFA-281 and ethanol. The main questions it aims to answer are: Does alcohol interact with AFA-281? What are the side effects (if any)? Researchers will compare AFA-281 to a placebo (a look-alike substance that contains no drug) to see if AFA-281 interacts with alcohol. Participants will take a total of 4 treatment sessions separated by at least 2 days between treatments. The treatments will incorporate AFA-281 or placebo with ethanol or ethanol placebo. After each treatment vital signs will be monitored and blood collected to measure AFA-281 and ethanol levels. Participants will provide an assessment survey of symptoms. The total treatment time will be 9 inpatient days (8 nights), and a final follow-up visit 3 to 5 days after clinic discharge.
Conditions
- Alcohol
- Alcohol Use Disorders
Interventions
AFA-281 is a small molecule, orally availableDrug
This is a study to evaluate the interaction of AFA-281 with alcohol
Alcohol (Ethanol)Other
Alcohol will be administered in combination with AFA-281 or AFA-281 placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic evaluation of AFA-281Time frame: Predose and 1, 2, 2.25, 2.5, 2.75, 3, 3.25, 4, 5, 6, 7, 8, 12 and 24 hours post dose
- Evaluation of ethanol levels in the bloodTime frame: Collected at 2, 2.25, 2.5, 2.75, 3, 3.25, 4, 5, 6, 7, 8, 12 and 24 hours post administration
- Dizziness visual analog scale (VAS) assessmentTime frame: Collected at predose, 1, 2, 3, 4, 6 and 8 hours post dose
- Choice Reaction Time (CRT) evaluationTime frame: Predose and 1, 2, 3, 4, 6 and 8 hours post dose
- Balance Platform assessmentTime frame: Predose and 1, 2, 3, 4, 6 and 8 hours post dose
- Match to Sample Visual Search (MTS) assessmentsTime frame: 1, 2, 4 and 8 hours post dose
- Alertness visual analog scale (AVAS)Time frame: 1, 2, 4 and 8 hours post dose
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.